Lexeo Therapeutics Signs $8.3M M&A Deal with Mantle Therapeutics Inc.
Lexeo Therapeutics completed its acquisition of Mantle Therapeutics for an upfront consideration of $5.3 million in cash and $3.0 million in common stock. The deal includes contingent payments of up to $13.0 million, consisting of a $1.0 million cash payment and $12.0 million in development and regulatory milestones over a 12-year term.
Lexeo Therapeutics Signs $8.3M M&A Deal with Mantle Therapeutics Inc.
Lexeo Therapeutics entered into a definitive agreement to acquire Mantle Therapeutics for an upfront purchase price of $5.3 million in cash and $3.0 million in common stock. The deal includes up to $12.0 million in contingent development and regulatory milestone payments plus a $1.0 million cash payment upon specific events, aimed at expanding Lexeo's Friedreich ataxia (FA) pipeline with new CNS-targeted modalities.